EGFR and non-small cell lung carcinoma: Afatinib, a second generation EGFR TKI which targets all members of ErbB family (Solca et al., 2012), proved the high efficacy in the first-line treatment of advanced NSCLC with EGFR mutations in many randomized controlled trials (RCTs) including LUX-Lung 3, 6 and 7 (Sequist et al., 2013; Wu et al., 2014; Park et al., 2016).